Floatz logo

Pepinemab

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Vaccinex Inc.monoclonal_antibodyPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

249 Active assets in the Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) cohort.

Asset / SponsorPhaseRating
Carboplatin
Akeso
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Akeso
Phase 3BB
Irinotecan
Neonc Technologies, Inc.
Phase 2BB
Tisotumab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2BB
Capecitabine
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

Pepinemab is also rated in:

Huntington diseaseDormant
B
Indicative ·
57 / 100
View asset →
osteosarcomaDormant
CCC
Indicative ·
52 / 100
View asset →
Recurrent Malignant Solid NeoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →